Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Temperature modulates systemic and central actions of thyroid hormones on BAT thermogenesis

  • Rial Pensado, Eva
  • Rivas Limeres, Verónica
  • Grijota Martínez, Carmen
  • Rodríguez Díaz, Amanda
  • Capelli, Vallentina
  • Barca Mayo, Olga
  • Nogueiras Pozo, Rubén
  • Mittag, Jens
  • Diéguez González, Carlos
  • López Pérez, Miguel A.
Thyroid hormones (THs) play a major role regulating energy balance and brown adipose tissue (BAT) thermogenesis, as well as body temperature, as shown in hyperthyroid patients. However, the current landscape of preclinical thyroid hormone models is complex. For example, while rats become catabolic after TH administration, mice gain weight; so, these differences in species need to be analyzed in detail and specially whether temperature could be a factor. Here, we aimed to investigate the effect of environmental temperature on those actions. Rats were subcutaneously treated with L-thyroxine (T4) or stereotaxically within the ventromedial nucleus of the hypothalamus (VMH) with triiodothyronine (T3) and housed at 23°C, 4°C or 30°C; energy balance, BAT thermogenesis and AMP-activated protein kinase (AMPK) in the VMH were analyzed. Our data showed that the effect of both systemic T4 of central T3 on energy balance and BAT thermogenesis was dependent upon environmental temperature. This evidence is of interest in the design of experimental settings highlighting the species-specific metabolic actions of THs, and in understanding its physiological role in the adaptation to temperature.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Hypothalamic GHRH

  • Diéguez González, Carlos
  • López Pérez, Miguel A.
  • Casanueva Freijo, Felipe
Despite initial discovery in pancreatic tumors, GHRH is a 44-amino acid peptide primarily expressed in the hypothalamus. Recent RNA sequencing clarifies GHRH expression: predominantly hypothalamic in humans, with some basal ganglia presence, while extending to additional central nervous system (CNS) regions in other species. GHRH binds to its G-protein coupled receptor (GHRHR) in the arcuate (ARC), ventromedial (VMH), and periventricular (PeN) nuclei of the hypothalamus to exert its effects. Notably, the highest non-brain expression is found in somatotroph cells of the pituitary, directly targeting growth hormone (GH) production. GHRH is the primary regulator of pulsatile GH secretion, counteracted by somatostatin. While early models proposed alternating GHRH/somatostatin bursts, others implicate somatostatin as the primary regulator of GH pulse timing. These models fail to fully explain species and gender differences, particularly regarding nutritional status. The discovery of ghrelin, acting via GHS-R1a on GHRH neurons, significantly advanced understanding of GH regulation. Ghrelin interacts intricately with GHRH, modulating its expression and neuronal activity. Ghrelin also exerts GHRH-independent GH stimulation and synergizes with GHRH. The crucial role of GHRH in GH regulation is demonstrated by its key involvement in the action of other GH regulators, such as leptin, neuropeptide Y (NPY), and orexins. However, these interactions have also revealed that the physiological effects of GHRH extend far beyond its canonical role as a GH secretagogue. In this context, GHRH is thought to be a key regulator of the sleep-wake cycle and may be involved in whole-body energy homeostasis. The objective of this review is to summarize the current knowledge on GHRH and to discuss the potential pleiotropic effect of this hypothalamic neuropeptide, far beyond its classical action as regulator of the somatotroph axis.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

SF1-specific deletion of the energy sensor AMPKγ2 induces obesity

  • Freire-Agulleiro, Óscar
  • Estévez Salguero, Ánxela
  • Ferreira, Vitor
  • González García, Ismael
  • Nogueiras Pozo, Rubén
  • Tena Sempere, Manuel
  • Diéguez González, Carlos
  • López Pérez, Miguel A.
Objective AMP-activated protein kinase (AMPK) is a heterotrimer complex consisting of a catalytic α subunit (α1, α2) with a serine/threonine kinase domain, and two regulatory subunits, β (β1, β2) and γ (γ1, γ2, γ3), encoded by different genes. In the hypothalamus, AMPK plays a crucial role in regulating energy balance, including feeding, energy expenditure, peripheral glucose and lipid metabolism. However, most research on hypothalamic AMPK has concentrated on the catalytic subunits AMPKα1 and AMPKα2, with little focus on the regulatory subunits. Methods To fill this gap of knowledge, we investigated the effects of selectively deleting the regulatory isoform AMPKγ2, which is a primary “energy sensor”, in steroidogenic factor 1 (SF1) neurons of the ventromedial hypothalamic nucleus (VMH). Complete metabolic phenotyping and molecular analyses in brown adipose tissue (BAT), white adipose tissue (WAT) and liver were carried out. Results Our findings reveal that, in contrast to the obesity-protective effect of the genetic deletion of AMPKα subunits, the loss of AMPKγ2 in SF1 neurons leads to a sex-independent and feeding-independent obesity-prone phenotype due to decreased thermogenesis in brown adipose tissue (BAT) and reduced browning of WAT, resulting in lower energy expenditure. Additionally, SF1-Cre AMPKγ2 mice exhibit hepatic lipid accumulation, but surprisingly maintain normal glucose homeostasis. Conclusions Overall, these results highlight the distinct roles of AMPK subunits within the hypothalamus.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Hypothalamic astrocytic-BMAL1 regulates energy homeostasis in a sex-dependent manner

  • Luengo Mateos, María
  • Gonzalez Vila, Antía
  • Vicente Dragano, Nathalia Romanelli
  • Ohinska, Nataliia
  • Silveira Loureiro, María
  • González Domínguez, Marco
  • Estévez Salguero, Ánxela
  • Novelle Rodriguez, Paula
  • López Pérez, Miguel A.
  • Barca Mayo, Olga
Here, we demonstrate that hypothalamic astrocytic BMAL1 computes cyclic metabolic information to optimize energetic resources in a sexually dimorphic manner. Knockdown of BMAL1 in female astrocytes leads to negative energy balance and alters basal metabolic cycles without affecting circadian locomotor activity. Thus, astrocytic BMAL1 contributes to the control of energy balance through the modulation of the metabolic rate, hepatic and white adipose tissue lipogenesis, and the activity of brown adipose tissue. Importantly, most of these alterations are specific to hypothalamic astrocytic BMAL1. Moreover, female mice with BMAL1 knockdown in astrocytes exhibited a “male-like” metabolic obese phenotype when fed a high-fat diet. Overall, our results suggest a sexually dimorphic effect of astrocytic BMAL1 on the regulation of energy homeostasis, which may be of interest in the physiopathology of obesity and related comorbidities.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Fezolinetant for menopausal hot flashes and night sweats

  • González García, Ismael
  • López Pérez, Miguel A.
Fezolinetant acts on the NK3Rs expressed in kisspeptin neurons and glutamatergic MnPO neurons that receive projections from the kisspeptin neurons. This targeted mechanism allows fezolinetant to address the underlying neuroendocrine and thermoregulatory dysregulation associated with VMS, providing a focused therapeutic approach. Antagonism of the NKB effects inhibits both kisspeptin neuronal action and the activation of the MnPO neurons, ameliorating the VMS.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Defective Olfactomedin-2 connects adipocyte dysfunction to obesity

  • Lluch, Aina
  • Latorre, Jèssica
  • Espadas Villanueva, Isabel
  • Oliveras-Cañellas, Núria
  • Moreno-Navarrete, José M.
  • Caballano-Infantes, Estefanía
  • Sarker, Gitalee
  • Malvido, Nicolás F.
  • Garrido-Gil, Pablo
  • Labandeira-García, José L.
  • Nakaya, Naoki
  • Mora, Silvia
  • Chicano, Eduardo
  • López-Alcalá, Jaime
  • Malagón, María M.
  • Martín-Montalvo, Alejandro
  • Zhang, Birong
  • Zhou, You
  • Domingos, Ana I.
  • López, Miguel
  • Pörschke, Johanna
  • Gómez-Serrano, María
  • Szymanski, Witold
  • Graumann, Johannes
  • Tomarev, Stanislav I.
  • González-García, Ismael
  • Fernández-Real, José M.
  • Ortega, Francisco J.
Olfactomedin-2 (OLFM2) is a pleiotropic glycoprotein emerging as a regulator of energy homeostasis. We here show the expression of OLFM2 to be adipocyte-specific and inversely associated with obesity. OLFM2 levels increase during adipogenesis and are suppressed in inflamed adipocytes. Functionally, OLFM2 deficiency impairs adipocyte differentiation, while its over-production enhances the adipogenic transformation of fat cell progenitors. Loss and gain of function experiments revealed that OLFM2 modulates key metabolic and structural pathways, including PPAR signaling, citrate cycle, fatty acid degradation, axon guidance and focal adhesion in 3T3 cell lines and primary human adipocytes. On the molecular level, OLFM2 deficiency in differentiated adipocytes predominantly downregulates genes involved in cell cycle. Extending these findings in vivo, both whole-body Olfm2 knockout and adipose-specific Olfm2 depletion in mice resulted in impaired adipose cell cycle gene expression, with the latter also displaying fat mass accretion and metabolic dysfunction. Collectively, our results underscore a critical role for OLFM2 in adipocyte biology, and support a causative link between reduced adipose OLFM2 and the pathophysiology of obesity., This study has been funded by the Instituto de Salud Carlos III (ISCIII), through the projects CP19/00109, PI18/00550, and PI21/00074 (to F.J.O.), the Ministerio de Ciencia e Innovación (PID2022-141115NA-I00 to I.G.-G.; PID2022-142951OB-I00 to S.M.; PID2021-128145NB-I00 and PDC2022-133958-I00, to M.L.), and the Xunta de Galicia (ED431C 2024/10 and ED431F 2024/14, to I.G.-G.), also co-founded by the European Union and the Fondo Europeo de Desarrollo Regional (FEDER). F.J.O. (MS19/00109) is recipient of the Miguel Servet scheme (ISCIII), A.L. (FI19/00045) is recipient of a Contrato Predoctoral de Formación en Investigación en Salud (PFIS, ISCIII), I.G.-G. is supported by a Ramón y Cajal award (RYC2021-031225-I), and N.F.M. is recipient of a Contrato Predoctoral para la Formación de Doctores (PREP2022-000775), Ministerio de Ciencia, Innovación y Universidades, Gobierno de España (ES). N.N. and S.I.T. were supported by the Intramural Research Programs of the National Eye Institute, NIH. The authors thank the CERCA and PERIS programmes (Generalitat de Catalunya) for financial and institutional support, and are indebted to the participants of the FATBANK platform, promoted by the Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN, ISCIII) and the Institut d’Investigació Biomèdica de Girona (IDIBGI) Biobank (Biobanc IDIBGI, B.0000872), integrated in the Spanish National Biobanks Network, for their collaboration and coordination. We would like to thank the Animal Facility of the Barcelona Science Park and its staff for the technical assistance provided in carrying out the tasks related to the work with animals. The authors are also indebted to the IMIM Microarray Analysis Service (Hospital del Mar Medical Research Institute, Barcelona, Spain) for technical guidance., Peer reviewed